ACTU NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Actuate Therapeutics, Inc. Common stock · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 1.11 USD
-5.9% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -61.0% below the Trend Line and sits at 1.0% of its 52-week range. The latest completed week returned -5.9%, after a -27.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 48/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 14 out of 100
Latest Close 1.11 USD 31 Jul 2026
1W Return -5.9% latest completed week
4W Return -27.0% short-term follow-through
12W Return -66.4% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -5.9% Latest completed week; four-week move -27.0%. Indicator stack 0/30 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 39.65% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 48/100 63 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -61.0% below the Trend Line and sits at 1.0% of its 52-week range. The latest completed week returned -5.9%, after a -27.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0112-week average 0.08

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.01Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -27.0% over four weeks, -66.4% over 12 weeks, and -84.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-5.9%
4W-27.0%
12W-66.4%
26W-76.4%
52W-84.7%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.26Latest activity-pressure read.
Pressure change-184.7%Four-week change in activity pressure.
Leadership-78.89Latest relative-leadership reading.
RS change-5.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 61% Model confidence 58%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength75/100Blend of value, momentum, and quality. Underlying universe rank 26; rank 1 is best.
Value62/100Relative valuation strength. Underlying universe rank 39; rank 1 is best.
Quality60/100Profitability and accounting quality. Underlying universe rank 41; rank 1 is best.
Momentum62/100Medium-term price momentum. Underlying universe rank 39; rank 1 is best.
Growth62/100Revenue and earnings growth. Underlying universe rank 39; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-95.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-86.8%
Net share repurchases relative to market value.
Shareholder yield
-86.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment48/100

Weighted news tone is neutral across 63 relevant articles.

11 positive · 38 neutral · 14 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-88.0%Distance below the 52-week high.
13-week volatility12.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher8 of 2618 weeks finished lower.
Best week+34.3%Week of 17 Apr.
Worst week-30.6%Week of 10 Apr.
Latest week-5.9%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains2
Flat weeks0
Modest losses1
Sharp losses17
Recent vol12.3%13-week weekly-return volatility.
Base vol12.4%52-week weekly-return volatility.
Up/down split19/33Count of positive and negative weeks in the 52-week window.
Average skew9.6% / -9.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape16/100

Trend, activity pressure, participation, and risk combine to a 16/100 tape read.

 Indicator analysis26/100

Latest 12-week confirmation: trend 0/12, activity pressure 10/12, relative leadership 0/12.

Activity pressure 0.01; No reversal markers Next-Week ExpectancyNegative 39.65%

Next-week expectancy is negative with a 39.65% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors64/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 100 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment48/100

Weighted news tone is neutral across 63 relevant articles.

Actuate Therapeutics stock initiated with buy rating at Rodman & Renshaw Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20261.11 USD-5.9%2.84 USD6.39 USD-0.26-78.89927.0KOff
24 Jul 20261.18 USD-18.1%3.01 USD6.44 USD-0.06-78.08594.7KOff
17 Jul 20261.44 USD19.0%3.18 USD6.49 USD0.19-74.376.0MOff
10 Jul 20261.21 USD-20.4%3.37 USD6.54 USD0.14-79.761.3MOff
3 Jul 20261.52 USD-9.5%3.58 USD6.59 USD0.31-74.67629.5KOff
26 Jun 20261.68 USD-18.8%3.77 USD6.65 USD0.31-72.381.3MOff
19 Jun 20262.07 USD2.5%3.97 USD6.70 USD0.24-68.10348.1KOff
12 Jun 20262.02 USD7.4%4.11 USD6.75 USD0.22-68.831.7MOff
5 Jun 20261.88 USD-6.9%4.24 USD6.80 USD0.17-71.16441.5KOff
29 May 20262.02 USD-15.1%4.38 USD6.85 USD0.25-71.26545.3KOff
22 May 20262.38 USD-9.2%4.54 USD6.90 USD0.22-66.53398.6KOff
15 May 20262.62 USD-20.6%4.70 USD6.95 USD0.20-63.901.0MOff
8 May 20263.30 USD10.0%4.86 USD7.00 USD-0.13-56.05419.5KOff
1 May 20263.00 USD1.0%5.01 USD7.04 USD-0.50-59.09647.6KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.